Skip to main content
CSPC Pharmaceutical Group Limited logo

CSPC Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1093 ISIN · US12591J1088 LEI · 529900M3XQCW234H8O91 HKEX Manufacturing
Open in API
Filings indexed 1,523 across all filing types
Latest filing 2021-12-22 Regulatory Filings
Country HK Hong Kong
Listing HKEX 1093

About CSPC Pharmaceutical Group Limited

https://www.cspc.com.hk/en/global/home.…

CSPC Pharmaceutical Group Limited is a comprehensive enterprise specializing in the research, development, manufacturing, and sale of pharmaceutical products. The company operates across two main segments: finished drugs and bulk drugs. It emphasizes innovation and new drug development, evidenced by substantial R&D investment, to produce high-quality, effective, and reliable medicines. Its portfolio includes key innovative products such as NBP (soft capsules and injections), Oulaining, and Enxi, which are among its top-selling drugs.

Recent filings

Filing Released Lang Actions
CONTINUING CONNECTED TRANSACTIONS - RENEWAL OF MASTER PURCHASE AGREEMENT
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the renewal of a master purchase agreement between CSPC Pharmaceutical Group Limited and an associate company, CHL. It discusses continuing connected transactions under the Listing Rules of the Hong Kong Stock Exchange, including details about the agreement, annual caps, and regulatory implications. The document is structured as a formal announcement with no financial statements or detailed financial analysis. It is not a full annual or interim report, nor an earnings release or management discussion. It is also not a proxy solicitation, voting results, or a director dealing report. The content fits the category of a regulatory announcement about continuing connected transactions, which is typically classified under Regulatory Filings (RNS). The document length is about 11,915 characters, which is consistent with a detailed announcement but not a full report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2021-12-22 English
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by CSPC Pharmaceutical Group Limited. It details repurchases of shares on various dates, quantities, and prices, and confirms compliance with listing rules. The content is focused on reporting share repurchase transactions and changes in issued shares, which aligns with the category for reporting company buying back its own shares. The document is about actual transactions and not merely an announcement or summary, and it is not a full financial report or earnings release. Therefore, the appropriate classification is 'Transaction in Own Shares' (POS).
2021-12-14 English
VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN THE PHASE 1/2 CLINICAL TRIAL OF JMT601 IN THE U.S.
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CSPC Pharmaceutical Group Limited regarding the dosing of the first patient in a Phase 1/2 clinical trial of a drug candidate. It is not a financial report, earnings release, or regulatory filing related to financial performance. The content focuses on clinical trial progress and drug development, which is typical for a voluntary announcement to inform investors and the market about significant company developments. The document is relatively short (3593 characters) and does not contain financial statements or detailed financial data. It is not an announcement of voting results, board changes, or capital changes. Therefore, it fits best under the category of a Regulatory Filing (RNS) as a general announcement that does not fit other specific categories.
2021-12-14 English
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by CSPC Pharmaceutical Group Limited. It includes detailed data on repurchases of shares, dates, quantities, prices, and confirmations of compliance with listing rules on the Stock Exchange of Hong Kong. The content focuses on share repurchase activities and disclosures required by stock exchange rules. It is not a full financial report, earnings release, or management discussion. It is a regulatory disclosure about share capital changes and repurchases. This fits the category of Transaction in Own Shares (POS), which covers reports of the company buying back or selling its own shares.
2021-12-13 English
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares Classification · 100% confidence The document is a Next Day Disclosure Return related to changes in issued share capital and share buybacks by CSPC Pharmaceutical Group Limited. It details repurchases of shares on specific dates, quantities, and prices, and confirms compliance with listing rules. The content focuses on share repurchase activity and capital changes rather than financial results, management commentary, or regulatory certifications. The document is about share buybacks and changes in issued share capital, which fits the definition of Transaction in Own Shares (POS). The document length is 9305 characters, which is substantive and contains detailed data, not just an announcement or certification. Therefore, the appropriate classification is POS.
2021-12-10 English
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by CSPC Pharmaceutical Group Limited. It details repurchases of shares on specific dates, quantities, and prices, and confirms compliance with listing rules. The document is a regulatory disclosure about share repurchases and capital changes, not a full financial report or earnings release. It fits the definition of a 'Transaction in Own Shares' filing, which reports company buybacks or sales of its own shares. The document length and content confirm it is not a brief announcement or a certification but a detailed disclosure of share repurchase transactions.
2021-12-08 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.